chronic myeloid leukaemia

Oncology

Targeting blood cancers with high unmet need

When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.

Oncology

pharmaphorum podcast Episode 205a - Amy Burroughs, Terns Pharmaceuticals

Doing good in people’s lives: Amy Burroughs discusses CML

Amy Burroughs, CEO, Terns Pharmaceuticals, discusses available treatments for CML, the potential of allosteric TKIs, and the wider oncology landscape.

News

Novartis gets FDA okay for frontline use of Scemblix in CML

Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential.

News

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).

News

Medicines Patent Pool, Novartis pen deal to boost access to ...

The Medicines Patent Pool (MPP) and Novartis have unveiled a new

News

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).

Targeting blood cancers with high unmet need

Doing good in people’s lives: Amy Burroughs discusses CML

Novartis gets FDA okay for frontline use of Scemblix in CML

ASCO: Novartis’ Scemblix aces first-line CML study

Medicines Patent Pool, Novartis pen deal to boost access to ...

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

chronic myeloid leukaemia

Editor's Picks